Brokers Issue Forecasts for PACB FY2025 Earnings

Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Pacific Biosciences of California in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn anticipates that the biotechnology company will post earnings per share of ($0.62) for the year. The consensus estimate for Pacific Biosciences of California's current full-year earnings is ($0.91) per share.

Other equities research analysts also recently issued reports about the stock. Piper Sandler boosted their target price on shares of Pacific Biosciences of California from $2.00 to $2.50 and gave the stock a "neutral" rating in a research report on Monday, November 11th. UBS Group lowered Pacific Biosciences of California from a "buy" rating to a "neutral" rating and set a $2.00 target price on the stock. in a report on Monday, November 11th. The Goldman Sachs Group lowered their price target on Pacific Biosciences of California from $2.25 to $1.75 and set a "neutral" rating for the company in a research report on Thursday. Scotiabank cut their price objective on shares of Pacific Biosciences of California from $7.00 to $6.00 and set a "sector outperform" rating on the stock in a report on Monday, November 11th. Finally, StockNews.com upgraded shares of Pacific Biosciences of California to a "sell" rating in a report on Thursday, January 9th. One research analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $2.89.

Pacific Biosciences of California Stock Down 8.8 %

PACB stock traded down $0.16 during midday trading on Wednesday, reaching $1.65. 19,999,031 shares of the company's stock traded hands, compared to its average volume of 11,328,510. The company has a quick ratio of 8.64, a current ratio of 9.74 and a debt-to-equity ratio of 1.97. The firm's fifty day moving average price is $1.89 and its 200-day moving average price is $1.82. Pacific Biosciences of California has a 52 week low of $1.16 and a 52 week high of $7.50. The company has a market cap of $451.87 million, a price-to-earnings ratio of -1.13 and a beta of 1.95.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Water Island Capital LLC boosted its position in shares of Pacific Biosciences of California by 91.1% in the second quarter. Water Island Capital LLC now owns 20,000 shares of the biotechnology company's stock valued at $27,000 after acquiring an additional 9,537 shares during the period. PCA Investment Advisory Services Inc. grew its position in shares of Pacific Biosciences of California by 50.0% during the 4th quarter. PCA Investment Advisory Services Inc. now owns 15,000 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 5,000 shares in the last quarter. Atom Investors LP bought a new position in shares of Pacific Biosciences of California in the third quarter worth $30,000. Atria Investments Inc raised its position in shares of Pacific Biosciences of California by 85.7% in the third quarter. Atria Investments Inc now owns 21,968 shares of the biotechnology company's stock worth $37,000 after buying an additional 10,138 shares in the last quarter. Finally, Centiva Capital LP bought a new stake in Pacific Biosciences of California during the third quarter valued at $40,000.

Insider Buying and Selling

In related news, insider Oene Mark Van sold 34,405 shares of the business's stock in a transaction on Friday, January 10th. The stock was sold at an average price of $2.03, for a total transaction of $69,842.15. Following the sale, the insider now directly owns 1,597,454 shares in the company, valued at approximately $3,242,831.62. The trade was a 2.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.40% of the stock is owned by insiders.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.